论文部分内容阅读
目的探讨急性脑梗死患者血清基质金属蛋白酶-9(MMP-9)含量的变化及依达拉奉对其的影响,并分析其临床意义。方法选择120例经CT或MR I确诊的发病在48 h内的脑梗死患者随机分为依达拉奉组和常规治疗组,分别于治疗前、治疗第7、14、21天后检测2组患者的血清MMP-9水平,并对2组患者的神经功能缺损程度进行评分。结果治疗前2组患者血清MMP-9水平间差异无统计学意义(P>0.05);依达拉奉组治疗后第7、14、21天的MMP-9水平与常规治疗组比较差异均有统计学意义(P<0.05)。治疗前2组患者神经功能缺损评分比较差异无统计学意义(P>0.05);依达拉奉组治疗后第7、14、21天的神经功能缺损评分与常规治疗组相应时间的评分比较差异均有统计学意义(P<0.05)。并且治疗后随时间推移MMP-9浓度下降及神经功能缺损评分改善更加明显。结论依达拉奉可以显著降低急性脑梗死患者血清MMP-9水平,能有效改善急性脑梗死患者的神经功能缺损。
Objective To investigate the changes of serum matrix metalloproteinase-9 (MMP-9) in patients with acute cerebral infarction and the effect of edaravone on it, and to analyze its clinical significance. Methods A total of 120 patients with cerebral infarction diagnosed by CT or MR I within 48 hours were randomly divided into edaravone group and conventional treatment group. Before treatment, on the 7th, 14th and 21st days after treatment, two groups of patients Serum MMP-9 levels, and two groups of patients with neurological deficit score. Results There was no significant difference in serum MMP-9 levels between the two groups before treatment (P> 0.05). The MMP-9 levels at 7, 14 and 21 days after edaravone treatment were significantly lower than those in the conventional treatment group Statistical significance (P <0.05). There was no significant difference in neurological deficit score between the two groups before treatment (P> 0.05). The score of neurological deficit score on the 7th, 14th and 21st day after treatment in edaravone group was significantly lower than that in the conventional treatment group All were statistically significant (P <0.05). And after treatment, the decrease of MMP-9 concentration and improvement of neurological deficit score were more obvious. Conclusion Edaravone can significantly reduce serum MMP-9 levels in patients with acute cerebral infarction, and can effectively improve the neurological deficits in patients with acute cerebral infarction.